Immunotherapy for solid tumors - A review for surgeons

Journal of Surgical Research

Volumn 187, Issue 2, 2014, Pages 525-535

  Saied, Abdul ^a   Pillarisetty, Venu G ^b   Katz, Steven C ^a,c  

^a ROGER WILLIAMS MEDICAL CENTER   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adoptive cell transfer therapy; Immunotherapy; Solid tumors

Indexed keywords

ANTINEOPLASTIC AGENT; CANCER VACCINE; IMMUNOMODULATING AGENT; MONOCLONAL ANTIBODY;

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; APOPTOSIS; CANCER CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER SURGERY; CELL FUNCTION; CELL TRANSPLANTATION; HUMAN; IMMUNE DEFICIENCY; IMMUNE EVASION; IMMUNE RESPONSE; IMMUNE SYSTEM; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; SOLID TUMOR; SURGEON; T LYMPHOCYTE; TUMOR CELL; TUMOR ESCAPE; TUMOR MICROENVIRONMENT;

ADOPTIVE CELL TRANSFER THERAPY; IMMUNOTHERAPY; SOLID TUMORS;

CANCER VACCINES; COMBINED MODALITY THERAPY; GENERAL SURGERY; HUMANS; IMMUNOTHERAPY, ADOPTIVE; NEOPLASMS;

EID: 84900564666     PISSN: 00224804     EISSN: 10958673     Source Type: Journal    
DOI: 10.1016/j.jss.2013.12.018     Document Type: Review

References (109)

1. W.B. Coley II. Contribution to the knowledge of sarcoma Ann Surg 14 1891 199
2. K.W. Clauberg [The immunobiological legacy of Emil von Behring and Paul Ehrlich] Dtsch Med J 5 1954 138
3. M. Burnet Cancer - a biological approach Br Med J 1 1957 779
4. L. Thomas, and H.S. Lawrence Cellular and humoral aspects of the hypersensitive states 1959 Hoeber-Harper New York 529 532
5. O. Stutman Immunodepression and malignancy Adv Cancer Res 22 1975 261
6. R.D. Schreiber, L.J. Old, and M.J. Smyth Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion Science 331 2011 1565
7. S.A. Rosenberg, N.P. Restifo, J.C. Yang, R.A. Morgan, and M.E. Dudley Adoptive cell transfer: a clinical path to effective cancer immunotherapy Nat Rev Cancer 8 2008 299
8. A. Knuth, B. Danowski, H.F. Oettgen, and L.J. Old T-cell-mediated cytotoxicity against autologous malignant melanoma: analysis with interleukin 2-dependent T-cell cultures Proc Natl Acad Sci 81 1984 3511
9. U. Sahin, O. Türeci, and H. Schmitt et al. Human neoplasms elicit multiple specific immune responses in the autologous host Proc Natl Acad Sci 92 1995 11810
10. S.A. Rosenberg, Y. Kawakami, P.F. Robbins, and R. Wang Identification of the genes encoding cancer antigens: implications for cancer immunotherapy Adv Cancer Res 70 1996 145
11. I. Nukaya, M. Yasumoto, and T. Iwasaki et al. Identification of HLA-A24 epitope peptides of carcinoembryonic antigen which induce tumor-reactive cytotoxic T lymphocyte Int J Cancer 80 1999 92
12. M.A. Cheever, J.P. Allison, and A.S. Ferris et al. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research Clin Cancer Res 15 2009 5323
13. S.C. Katz, C. Donkor, and K. Glasgow et al. T cell infiltrate and outcome following resection of intermediate-grade primary neuroendocrine tumours and liver metastases HPB (Oxford) 12 2010 674
14. S.C. Katz, Z.M. Bamboat, and A.V. Maker et al. Regulatory T cell infiltration predicts outcome following resection of colorectal cancer liver metastases Ann Surg Oncol 20 2013 946
15. T.F. Gajewski Failure at the effector phase: immune barriers at the level of the melanoma tumor microenvironment Clin Cancer Res 13 2007 5256
16. S.C. Katz, V. Pillarisetty, and Z.M. Bamboat et al. T cell infiltrate predicts long-term survival following resection of colorectal cancer liver metastases Ann Surg Oncol 16 2009 2524
17. J. Galon, A. Costes, and F. Sanchez-Cabo et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome Science 313 2006 1960
18. L. Zhang, J.R. Conejo-Garcia, and D. Katsaros et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer New Engl J Med 348 2003 203
19. J.F. Vansteenkiste, M. Zielinski, and I.J. Dahabreh et al. Association of gene expression signature and clinical efficacy of MAGE-A3 antigenspecific cancer immunotherapeutic (ASCI) as adjuvant therapy in resected stage IB/II non-small cell lung cancer (NSCLC) J Clin Oncol 26 2008 7501
20. B. Mlecnik, M. Tosolini, and A. Kirilovsky et al. Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction J Clin Oncol 29 2011 610
21. S. Bodmer, K. Strommer, and K. Frei et al. Immunosuppression and transforming growth factor-beta in glioblastoma. Preferential production of transforming growth factor-beta 2 The J Immunol 143 1989 3222
22. B. Bierie, and H.L. Moses Transforming growth factor beta (TGF-β) and inflammation in cancer Cytokine growth factor rev 21 2010 49
23. Y.Y. Wan, and R.A. Flavell TGF-β and regulatory T cell in immunity and autoimmunity J clin immunol 28 2008 647
24. D.B. Constam, J. Philipp, U.V. Malipiero, P. Ten Dijke, M. Schachner, and A. Fontana Differential expression of transforming growth factor-beta 1,-beta 2, and-beta 3 by glioblastoma cells, astrocytes, and microglia The J Immunol 148 1992 1404
25. W.T. Couldwell, P. Dore-Duffy, M.L. Apuzzo, and J.P. Antel Malignant glioma modulation of immune function: relative contribution of different soluble factors J Neuroimmunol 33 1991 89
26. G.Y. Chau, C.W. Wu, and W.Y. Lui et al. Serum interleukin-10 but not interleukin-6 is related to clinical outcome in patients with resectable hepatocellular carcinoma Ann Surg 231 2000 552
27. A.H. Sarris, K.-O. Kliche, and P. Pethambaram et al. Interleukin-10 levels are often elevated in serum of adults with Hodgkin's disease and are associated with inferior failure-free survival Ann Oncol 10 1999 433
28. S. Viviani, P. Notti, V. Bonfante, P. Verderio, P. Valagussa, and G. Bonadonna Elevated pretreatment serum levels of Il-10 are associated with a poor prognosis in Hodgkin's disease, the Milan cancer institute experience Med Oncol 17 2000 59
29. M.R. Young, M.A. Wright, Y. Lozano, J.P. Matthews, J. Benefield, and M.M. Prechel Mechanisms of immune suppression in patients with head and neck cancer: influence on the immune infiltrate of the cancer Int J Cancer 67 1996 333
30. H. Sheng, J. Shao, J.D. Morrow, R.D. Beauchamp, and R.N. DuBois Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells Cancer Res 58 1998 362
31. M. Huang, S. Sharma, J.T. Mao, and S.M. Dubinett Non-small cell lung cancer-derived soluble mediators and prostaglandin E2 enhance peripheral blood lymphocyte IL-10 transcription and protein production The J Immunol 157 1996 5512
32. D.C. Gondek, L.-F. Lu, S.A. Quezada, S. Sakaguchi, and R.J. Noelle Cutting edge: contact-mediated suppression by CD4+ CD25+ regulatory cells involves a granzyme B-dependent, perforin-independent mechanism The J Immunol 174 2005 1783
33. F. Fallarino, U. Grohmann, and K.W. Hwang et al. Modulation of tryptophan catabolism by regulatory T cells Nat immunol 4 2003 1206
34. C.G. Drake, E. Jaffee, and D.M. Pardoll Mechanisms of immune evasion by tumors Adv immunol 90 2006 51
35. F. Ghiringhelli, C. Ménard, and M. Terme et al. CD4+ CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-β-dependent manner The J Exp Med 202 2005 1075
36. W.J. Grossman, J.W. Verbsky, W. Barchet, M. Colonna, J.P. Atkinson, and T.J. Ley Human T regulatory cells can use the perforin pathway to cause autologous target cell death Immunity 21 2004 589
37. A.L. Mellor, and D.H. Munn IDO expression by dendritic cells: tolerance and tryptophan catabolism Nat Rev Immunol 4 2004 762
38. C. Fortis, M. Foppoli, and L. Gianotti et al. Increased interleukin-10 serum levels in patients with solid tumours Cancer Lett 104 1996 1
39. O. Janssen, R. Sanzenbacher, and D. Kabelitz Regulation of activation-induced cell death of mature T-lymphocyte populations Cell Tissue Res 301 2000 85
40. O.J. Finn Cancer immunology N Engl J Med 358 2008 2704
41. F.S. Hodi, S.J. O'Day, and D.F. McDermott et al. Improved survival with ipilimumab in patients with metastatic melanoma New Engl J Med 363 2010 711
42. J.R. Brahmer, S.S. Tykodi, and L.Q. Chow et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer N Engl J Med 366 2012 2455
43. T.J. Curiel, S. Wei, and H. Dong et al. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity Nat Med 9 2003 562
44. M. Kojima, T. Morisaki, and A. Uchiyama et al. Association of enhanced cyclooxygenase-2 expression with possible local immunosuppression in human colorectal carcinomas Ann surg oncol 8 2001 458
45. D. Kabelitz, T. Pohl, and K. Pechhold Activation-induced cell death (apoptosis) of mature peripheral T lymphocytes Immunol Today 14 1993 338
46. T.Z. Zaks, D.B. Chappell, S.A. Rosenberg, and N.P. Restifo Fas-mediated suicide of tumor-reactive T cells following activation by specific tumor: selective rescue by caspase inhibition J Immunol 162 1999 3273
47. M.A. Curran, W. Montalvo, H. Yagita, and J.P. Allison PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors Proc Natl Acad Sci 107 2010 4275
48. S.L. Topalian, F.S. Hodi, and J.R. Brahmer et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer New Engl J Med 366 2012 2443
49. O. Hamid, C. Robert, and A. Daud et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma N Engl J Med 369 2013 134
50. J.D. Wolchok, H. Kluger, and M.K. Callahan et al. Nivolumab plus ipilimumab in advanced melanoma N Engl J Med 369 2013 122
51. L.A. Licata, C.T. Nguyen, and R.A. Burga et al. Biliary obstruction results in PD-1-dependent liver T cell dysfunction and acute inflammation mediated by Th17 cells and neutrophils J Leukoc Biol 94 2013 813
52. N.A. Hutchins, F. Wang, Y. Wang, C.-S. Chung, and A. Ayala Kupffer cells potentiate liver sinusoidal endothelial cell injury in sepsis by ligating programmed cell death ligand-1 Journal of Leuko Biol 94 2013 963
53. A. Ribas Tumor immunotherapy directed at PD-1 N Engl J Med 366 2012 2517
54. W. Zou Regulatory T cells, tumour immunity and immunotherapy Nat Rev Immunol 6 2006 295
55. E.M. Shevach CD4+ CD25+ suppressor T cells: more questions than answers Nat Rev Immunol 2 2002 389
56. T.J. Curiel, G. Coukos, and L. Zou et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival Nat Med 10 2004 942
57. R.F. Gabitass, N.E. Annels, D.D. Stocken, H.A. Pandha, and G.W. Middleton Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13 Cancer Immunol Immunother 60 2011 1419
58. T. Fujimura, K. Mahnke, and A.H. Enk Myeloid derived suppressor cells and their role in tolerance induction in cancer J Dermatol Sci 59 2010 1
59. J. Kao, E.C. Ko, S. Eisenstein, A.G. Sikora, S. Fu, and S. Chen Targeting immune suppressing myeloid-derived suppressor cells in oncology Crit rev oncology/hematology 77 2011 12
60. B. Almand, J.I. Clark, and E. Nikitina et al. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer The J Immunol 166 2001 678
61. J.M. Kirkwood, M.H. Strawderman, M.S. Ernstoff, T.J. Smith, E.C. Borden, and R.H. Blum Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684 J Clin Oncol 14 1996 7
62. S.A. Rosenberg, J.C. Yang, and S.L. Topalian et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2 JAMA 271 1994 907
63. S.A. Rosenberg, P. Spiess, and R. Lafreniere A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes Science 233 1986 1318
64. E.F. McCarthy The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas The Iowa Orthopaedic J 26 2006 154
65. R. Foa, A. Guarini, and B. Gansbacher IL2 treatment for cancer: from biology to gene therapy Br J Cancer 66 1992 992
66. B.J. Czerniecki, G.K. Koski, and U. Koldovsky et al. Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion Cancer Res 67 2007 1842
67. M.L. Disis, K. Schiffman, and K. Guthrie et al. Effect of dose on immune response in patients vaccinated with an her-2/neu intracellular domain protein-based vaccine J Clin Oncol 22 2004 1916
68. C. Butts, N. Murray, and A. Maksymiuk et al. Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer J Clin Oncol 23 2005 6674
69. S.L. Bernhardt, M.K. Gjertsen, and S. Trachsel et al. Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: a dose escalating phase I/II study Br J Cancer 95 2006 1474
70. P. Gould Sipuleucel-T shows partial advantage in prostate cancer Lancet Oncol 7 2006 710
71. P.W. Kantoff, C.S. Higano, and N.D. Shore et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer New Engl J Med 363 2010 411
72. S.A. Rosenberg Cell transfer immunotherapy for metastatic solid cancer - what clinicians need to know Nat Rev Clin Oncol 8 2011 577
73. S.A. Rosenberg, M.T. Lotze, and L.M. Muul et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer The New Engl J Med 313 1985 1485
74. P.A. Antony, C.A. Piccirillo, and A. Akpinarli et al. CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells The J Immunol 174 2005 2591
75. L. Gattinoni, S.E. Finkelstein, and C.A. Klebanoff et al. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells The J Exp Med 202 2005 907
76. M.E. Dudley, J.C. Yang, and R. Sherry et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens J Clin Oncol 26 2008 5233
77. S.A. Rosenberg, J.C. Yang, and R.M. Sherry et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy Clin Cancer Res 17 2011 4550
78. R.A. Morgan, M.E. Dudley, and J.R. Wunderlich et al. Cancer regression in patients after transfer of genetically engineered lymphocytes Science 314 2006 126
79. G. Gross, T. Waks, and Z. Eshhar Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity Proc Natl Acad Sci 86 1989 10024
80. M.A. Pule, B. Savoldo, and G.D. Myers et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma Nat Med 14 2008 1264
81. D.L. Porter, B.L. Levine, M. Kalos, A. Bagg, and C.H. June Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia New Engl J Med 365 2011 725
82. S.A. Grupp, M. Kalos, and D. Barrett et al. Chimeric antigen receptor-Modified T cells for acute lymphoid leukemia New Engl J Med 368 2013 1509
83. S.C. Katz, R.A. Burga, and S. Naheed et al. Anti-KIT designer T cells for the treatment of gastrointestinal stromal tumor J Transl Med 11 2013 46
84. D. Berd, and M.J. Mastrangelo Active immunotherapy of human melanoma exploiting the immunopotentiating effects of cyclophosphamide Cancer Invest 6 1988 337
85. E. Suzuki, V. Kapoor, A.S. Jassar, L.R. Kaiser, and S.M. Albelda Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity Clin Cancer Res 11 2005 6713
86. W.M. Liu, D.W. Fowler, P. Smith, and A.G. Dalgleish Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses Br J Cancer 102 2009 115
87. M.A. Postow, M.K. Callahan, and C.A. Barker et al. Immunologic correlates of the abscopal effect in a patient with melanoma New Engl J Med 366 2012 925
88. S.F. Slovin, C.S. Higano, and O. Hamid et al. Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study Ann Oncol 24 2013 1813
89. S.C. Formenti, and S. Demaria Combining radiotherapy and cancer immunotherapy: a paradigm shift J Natl Cancer Inst 105 2013 256
90. F.S. Hodi, M.C. Mihm, and R.J. Soiffer et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients Proc Natl Acad Sci U S A 100 2003 4712
91. G.Q. Phan, J.C. Yang, and R.M. Sherry et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma Proc Natl Acad Sci U S A 100 2003 8372
92. C. Robert, L. Thomas, and I. Bondarenko et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma N Engl J Med 364 2011 2517
93. M.S. Merchant A phase I study of ipilimumab (Anti-CTLA-4) in children, adolescents, and young adults with treatment refractory cancer 2013 National Institutes of Health Clinical Center (CC) http://clinicaltrials.gov/NCT01445379
94. L.C. Michele Maio A second-line, single arm, phase ii clinical study with tremelimumab, a fully human anti-ctla-4 monoclonal antibody, as monotherapy in patients with unresectable malignant mesothelioma. The MESOT-TREM-2012 2013 Azienda Ospedaliera Universitaria Senese Italy http://clinicaltrials.gov/ NCT01655888
95. J. Prieto-Valtuena Phase II trial of anti-ctla-4 human monoclonal antibody CP-675,206 in patients with advanced hepatocellular carcinoma 2012 Clinica Universidad de Navarra, Universidad de Navarra Pfizer, Spain http://clinicaltrials.gov/NCT01008358
96. P.S. Lawrence Fong A randomized phase 2 trial of Immediate vs. Delayed anti-CTLA4 blockade following sipuleucel-T treatment for prostate cancer immunotherapy 2013 The University of Texas MD Anderson Cancer Center, University of California San Francisco USA http://clinicaltrials.gov/NCT01804465
97. S.A. Rosenberg Phase II trial of single agent ipilimumab (MDX-010 anti CTLA-4) for subjects with Locally advanced or metastatic pancreatic adenocarcinoma 2013 Bristol-Myers Squibb, National Cancer Institute (NCI) MD, USA http://clinicaltrials.gov/NCT00112580
98. S.N. Khleif Sipuleucel-T, CT-011, and cyclophosphamide for advanced prostate cancer 2013 Georgia Regents University GA, USA http://clinicaltrials. gov/NCT01420965
99. B.-M. Squibb A phase I dose escalation study to investigate the safety, immunoregulatory activity, pharmacokinetics, and preliminary antitumor activity of anti-programmed-death-1 (PD-1) antibody (BMS-936558) in advanced hepatocellular carcinoma in subjects with or without chronic viral hepatitis 2013 Bristol-Myers Squibb USA http://clinicaltrials.gov/NCT01658878
100. B.-M. Squibb A phase 1 dose Escalation study of BMS-982470 (Recombinant Interleukin-21, rIL-21) in combination with BMS-936558 (Anti-PD-1) in subjects with advanced or metastatic solid tumors 2013 Bristol-Myers Squibb USA http://clinicaltrials.gov/NCT01629758
101. B.-M. Squibb An exploratory study of the biologic effects of BMS-936558 (Anti-PD-1 monoclonal antibody) treatment in subjects with advanced melanoma (unresectable or metastatic) 2013 Bristol-Myers Squibb USA http:// clinicaltrials.gov/NCT01621490
102. W.W. Overwijk, M.R. Theoret, and S.E. Finkelstein et al. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells J Exp Med 198 2003 569
103. C.U. Louis, B. Savoldo, and G. Dotti et al. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma Blood 118 2011 6050
104. S.C. Katz Phase I trial of intrahepatic infusion of 2nd Generation designer T cells for Cea-expressing liver metastases 2013 http://clinicaltrials. gov/NCT01373047
105. F. Thistlethwaite A phase II trial to assess the activity of NY-ESO-1 targeted T cells in advanced oesophagogastric cancer 2013 Roger Williams Medical Center RI, USA http://clinicaltrials.gov/NCT01373047
106. H. Weidong Clinical study of chimeric EGFR antigen receptor-modified T cells in chemotherapy refractory advanced solid tumors 2013 Chinese PLA General Hospital China http://clinicaltrials.gov/NCT01869166
107. H.S. Susan Slovin Adoptive transfer of autologous T cells targeted to prostate specific membrane antigen (PSMA) for the treatment of castrate metastatic prostate cancer (CMPC) 2013 Memorial Sloan-Kettering Cancer Center, US http://clinicaltrials.gov/NCT01140373
108. N. Ahmed Administration of HER2 chimeric antigen receptor expressing CMV-specific cytotoxic T cells ins patients with glioblastoma multiforme (HERT-GBM) 2013 Baylor College of Medicine, US http://clinicaltrials.gov/ NCT01109095
109. M.B. Atkins, M.T. Lotze, and J.P. Dutcher et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993 J Clin Oncol 17 1999 2105